title: DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
abstract: Vaccination against target antigens expressed by cancer cells has now become a realistic goal. DNA vaccines provide a direct link between identification of genetic markers in tumors and vaccine formulation. Simplicity of manufacture facilitates construction of vaccines against disease subsets or even for individual patients. To engage an immune system that exists to fight pathogens, we have developed fusion gene vaccines encoding tumor antigens fused to pathogen-derived sequences. This strategy activates high levels of T-cell help, the key to induction and maintenance of effective immunity. We have dissected the immunogenic tetanus toxin to obtain specific sequences able to activate antibody, CD4+, or CD8+ T cells to attack selected fused tumor antigens. Principles established in preclinical models are now being tested in patients. So far, objective immune responses against idiotypic antigen of neoplastic B cells have been observed in patients with B-cell malignancies and in normal transplant donors. These responses provide a platform for testing physical methods to improve DNA delivery and strategies to boost responses. For cancer, demands are high, because vaccines have to activate powerful immunity against weak antigens, often in a setting of immune damage or tolerance. Vaccination strategies against cancer and against microbes are sharing knowledge and technology for mutual benefit.
authors.affiliation: Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK. fs@soton.ac.uk
authors.forename: Freda K
authors.initials: FK
authors.lastname: Stevenson
authors.forename: Jason
authors.initials: J
authors.lastname: Rice
authors.forename: Christian H
authors.initials: CH
authors.lastname: Ottensmeier
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Thirdborough
authors.forename: Delin
authors.initials: D
authors.lastname: Zhu
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D019677:Artificial Gene Fusion; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D000922:Immunotoxins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D013744:Tetanus Toxin / Q000235:genetics / Q000276:immunology; D014611:Vaccination / Q000379:methods; D019444:Vaccines, DNA / Q000235:genetics* / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000922:Immunotoxins; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; D013744:Tetanus Toxin; D019444:Vaccines, DNA; C040635:tetanus toxin fragment C